Lecanemab over a two-year duration: Key insights from a regional specialty medical center.

ABSTRACT:

Background and objectives

The anti-amyloid monoclonal antibody lecanemab (Leqembi®) treats patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD). We sought to evaluate the incidence of amyloid-related imaging abnormalities) ARIA and other adverse events associated with lecanemab.

Design, setting, and participants

This retrospective and observational study features 187 patients who received at least one lecanemab infusion at our multidisciplinary Norton Neuroscience Institute Memory Center over a two-year duration (August 25, 2023-August 24, 2025).

Results

A total of 109 (58.3 %) patients were diagnosed with MCI, and 78 (41.7 %) had mild dementia prior to starting lecanemab. The mean age at the initial infusion was 73 years (Ran

SUBMITTER: Shields LBE 

PROVIDER: S-EPMC12860706 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature